Head and neck cancer is a major cause of morbidity and mortality in Hong Kong. HNC is wellknown for its heterogeneity in epidemiology, clinical behavior, clinic-pathological features and patient characteristics. Treatment strategies for this heterogeneous disease vary greatly in different parts of the world, depending on availability of resources, local expertise and experience. Extensive research in head and neck cancer, particularly nasopharyngeal carcinoma, has been conducted in Hong Kong in the past few decades. In this article, we will review the available local evidence and summarize common practice in management of head and neck cancer in Hong Kong.
Introduction
Head and neck cancer (HNC) accounts for more than 550 000 cases and 380 000 deaths worldwide annually (1) . Major risk factors of HNC include smoking, alcohol consumption and infection with oncogenic viruses, e.g. human papillomavirus (HPV) for oropharyngeal cancer (HPVOC) and Epstein-Barr virus (EBV) for nasopharyngeal cancer (NPC). Incidence of HNC varies greatly in different areas of the world, reflective of relative prevalence of risk factors.
In this article, we will review the epidemiology, management issues, past achievements and ongoing clinical studies of squamous cell carcinoma (SCC) of head and neck (HNSCC) and NPC in Hong Kong (HK).
Epidemiology of head and neck cancer in Hong Kong
NPC has a peculiarly skewed racial and geographic variation in distribution. It is rare in western countries but highly prevalent in Southeast Asia. The latest statistics from HK Cancer Registry showed that NPC ranked 10th commonest cancer in 2014 (2). The epidemiology of NPC showed a steady decrease in incidence since the 1980s. The age-standardized incidence rate (ASIR) steadily decreased from 28.5 in 1980-84 to 12.2 in 2010-14 per 100 000 males, and from 11.2 to 3.6 per 100 000 females (2,3). There is also an encouraging decrease in age-standardized mortality rate (ASMR) from 13.7 in 1980-84 to 4.4 in 2010-14 per 100 000 males, and from 4.5 to 1.1 per 100 000 females (2,3). This reflects a change in prevalence of risk factors in HK and improvement in treatment outcome.
The major etiological factors proposed for NPC pathogenesis include genetic susceptibility, EBV infection and environmental factors. In high risk population, genetic susceptibility to NPC has been mapped to the human leukocyte antigen (HLA) loci and adjacent genes in major histocompatibility complex (MHC) region on chromosome 6p21. Despite close association of EBV infection with NPC, the etiological role of EBV in NPC pathogenesis remains enigmatic. EBV infection in primary nasopharyngeal epithelial cells is uncommon and difficult to achieve. EBV does not transform primary nasopharyngeal epithelial cells into proliferative clones, which contrasts greatly with the well-documented ability of EBV to transform and immortalize primary B cells. Genetic alterations identified in premalignant nasopharyngeal epithelium may play crucial roles to support stable EBV infection (4) .
Tobacco smoking is postulated as a potential risk factor of NPC. A case-referent study supported the roles of tobacco smoking and family history on NPC development in HK Chinese, with adjusted odds ratio as high as 4.54 for ever-smokers with family history as compared with never-smokers without family history (5) . Furthermore, domestic incense burning, occupational exposure to chemical or welding fumes and cotton dust may also be associated with an increased risk of NPC (6, 7) . Although salted fish consumption is believed to be an important risk factor of NPC, recent studies showed less conclusive association after adjustments for decreasing tobacco and increasing vegetable consumption per capita during the same period (8) .
HPV is increasingly recognized as one of the most important causative factors in a subgroup of patients with HNC and there is marked increase in incidence of HPVOC in the west (9) . A HK study was performed to investigate the prevalence, clinic-pathological behavior and treatment outcomes of oropharyngeal SCC (10) . Subjects with oropharyngeal SCC treated between 2005 and 2009 were identified from hospital records and verified with HK Cancer Registry. Tumor specimens were then retrieved and tested for HPV DNA by polymerase chain reaction using the consensus primer GP5 + /GP6 + 52HK that had a reserve primer modified based on the HPV52 variants in HK (11) . E6/7 mRNA was chosen to be the marker of oncogenic involvement. 20.8% of oropharyngeal SCC and 29.0% of the tonsillar SCC were associated with HPV. Among all HPV positive cases, HPV-18 accounted for one case, while HPV-16 was identified in all other cases. On multivariate analysis, patients with HPVOC were significantly younger, more likely to be non-smokers/non-drinkers, had tumor involving palatine tonsils, presenting with early disease and exhibiting basaloid differentiation on histology. HPV positivity was shown to be an independent predictor for better 5-year overall survival (OS) and 5-year disease specific survival. Prospective trial is currently on progress to observe the trend of HPV-associated HNC in HK.
For oral cavity cancer in HK, there is a general downward trend of ASIR for men, from 2.2 in 1985-90 to 1.3 in 2000-14 (2), which correlates with a decrease in male smoking prevalence in HK (12). On the other hand, incidence of oral cavity cancer in women demonstrated a significant upward trend from 2001 onwards. Underlying reasons for this rising trend remain unknown, but changing economic and immigration situations have been postulated (13) . Table 1 shows the prevalence of smoking and changing pattern of HNC in HK.
Management and clinical researches of head and neck cancer in Hong Kong
Surgery Surgical access to tumors in head and neck region can be challenging, particularly for lesions in nasopharynx, skull base, oropharynx and hypopharynx. To achieve adequate exposure for radical resection of tumors in these regions, trauma to surrounding normal structures is often unavoidable. Maxillary swing operation for nasopharyngeal and central skull base tumors (14) , mandibulotomy for oropharyngeal tumors, and transcervical approach for laryngeal and hypopharygeal tumors are classical surgical approaches. While these approaches ensure wide resection of tumors, extensive wounds may lead to prolonged recovery and increased risk of complications. In order to minimize trauma to normal tissue while maximizing chance of organ preservation, minimally invasive approaches are emerging. In HK, Trans Oral Robotic Surgery (TORS) in head and neck region is becoming more popular. The da Vinci robotic surgical system (Intuitive Surgical Inc., Sunnyvale, CA, USA) allows a magnified, three-dimensional visualization of surgical field, allowing precise and tremor free surgical dissection, with the possibility of threehanded surgery (15) . In selected patients, TORS has been used for resection of early tumors of nasopharynx ( Fig. 1) , oropharynx, (17) . In salvage nasopharyngectomy for patients with early recurrent NPC, resection margin status is one of the most important prognostic factors. Local tumor control was significantly worse in patients with involved margins than those with close margins, which was, in turn, significantly worse than those with clear margins (18) . A whole-organ histopathological study demonstrated the histological characteristics of recurrent NPC (19) . After radiotherapy (RT), recurrent tumors appear as islands of tumor cells that are separated by cords of fibrous tissue and lympho-plasmacytic infiltrates. The phenomenon of submucosal invasion is extremely common and resection margin of at least 1.5 cm is required to achieve 95% chance of histologically clear resection margins.
Even with stringent follow-up protocol, locally advanced recurrence is not uncommon. These tumors are often close to or encasing internal carotid artery, eroding skull base and extending to intracranial cavity. Surgical management of these tumors is associated with high risk of neurovascular sequelae and intracranial infection. In the past, many of these patients were considered inoperable. With improved understanding of anatomy, better surgical technique and microvascular free flap reconstruction, and technological advances, e.g. intra-operative real time navigation, larger tumor can be resected safely with satisfactory oncological outcome. Highly selected patients may benefit from staged operations (20) . In the first stage, cerebral perfusion is secured using autologous radial artery or long saphenous vein as vascular conduit to establish a high-flow, extracranial-intracranial vascular bypass (Fig. 2) . In the second stage, tumor is resected en-bloc, together with native internal carotid artery, sphenoid sinus, carotid canal and cavernous sinus if necessary, via cranio-facial approach. The resultant defect at skull base is then reconstructed by microvascular free flaps. With staged operation, histologically clear resection margin was achieved in 81.8% of patients. No hospital mortality or neurovascular complication was observed. Apart from one patient who suffered from local recurrence and systemic metastasis within 6 months after surgery, the rest of the patients remained disease free to date.
Modified radical neck dissection is currently the standard of care for patients with node positive disease who are planned for surgical intervention, and role of selective neck dissection (SND) for neck staging is also well established for node negative SCC of tongue. However, role of SND for patients with local recurrent NPC after RT is not well defined and is associated with high risk of postoperative morbidities, especially those related to shoulder dysfunction (21) . With neck level IIB dissection, ischemic neuropathy of spinal accessory nerve is common, even with anatomical preservation of the nerve, 30% of patients reported at least moderate shoulder pain at rest, together with varying degree of functional disability. To reduce the morbidities associated with selective neck dissection, real time mapping of sentinel lymph nodes was investigated (22) . Intra-operative identification of sentinel lymph node is feasible using peri-tumoural injection of indocyanine green solution (Fig. 3) . This may provide accurate staging of neck lymph nodes, while sparing patients from morbidities associated with SND. Similar strategy is also worth studying in local recurrent HNSCC after RT.
Radiotherapy
Intensity-modulated radiation therapy (IMRT) is currently the standard of care in HK for those requiring RT, perhaps with the exception of T1 glottic cancer. Local studies on IMRT (Table 2) for NPC have demonstrated better locoregional control and preservation of salivary function (23) (24) (25) (26) . Although altered fractionation was shown to be superior to conventional RT alone (27) , it is not widely practiced here; particularly as advanced cases are mostly treated with concomitant chemoradiotherapy (CRT) and altered fractionation offers no improvement in survival when compared with standard fractionation in this situation (28, 29) .
An important challenge coming with IMRT is the potential risk of geographical miss due to the highly conformal dose distribution. A thorough understanding of the disease and nature of tumor spread is essential to delineate the appropriate target volumes. While accuracy of delineation can be enhanced by comprehensive pretreatment assessment incorporating endoscopy, MRI and PET scanning, establishing a standardized delineation protocol is important. Development of an international consensus guideline on primary tumor delineation for HNC is currently in progress. Furthermore, institutes should analyze their own treatment outcomes and failure patterns to optimize their delineation methods and the appropriate margins to be used (30) . Currently, Hong Kong NPC study group (HKNPCSG) NPC-1301 trial is reviewing long-term efficacy and safety of IMRT in all public oncology centers for non-metastatic NPC and the results are cordially awaited.
Anatomical variation in body contour, target volumes as well as normal organs can occur during the course of RT. Shrinkage of parotid glands has been observed, and significant weight loss that affects neck diameter at different levels is common (31) . Such variation affects the resultant dose distribution, often impairing target dose coverage and organs-at-risk (OAR) sparing. This led to the development of adaptive RT; CT or MRI are performed within the course of RT to assess the anatomical variation, and if necessary treatment is re-planned accordingly. Improvement in locoregional control and quality of life have been observed in NPC (32) . However, optimal timing for treatment re-planning is still an open question. Advanced planning technologies like "in-(treatment)-room" imaging, deformable image registration, knowledge-based treatment planning tools (33) etc., are being tested locally with an aim to enhance the efficiency of adaptive RT.
Furthermore, with the advent of functional imaging, it may be possible to determine and deliver the most appropriate dose to different parts of the target volumes with IMRT, optimizing the therapeutic ratio of individual patient treatment. RT dose escalation beyond 70 Gy based on functional imaging for the treatment of NPC is currently under active investigations in HK.
Proton beam radiation therapy (PRBT) is the next step forward for treatment of HNC in HK. PBRT allows better sparing of OAR when compared with IMRT, which translates into lower rates of toxicities clinically (34, 35) . Proton may also make re-irradiation for recurrent HNC possible (36) . PBRT centers have been established in other Asian countries, e.g. Japan, South Korea and Taiwan, as early as 1990s. PBRT is currently not available in HK, but is being commissioned and should be available for clinical service in 2020.
Systemic therapy

HNSCC
The role of CRT in management of locoregionally advanced HNC was established around three decades ago (37) . Ever since, CRT has been the standard of care for locoregionally advanced HNSCC in HK. CRT has also a role in adjuvant setting in disease with high risk features, i.e. involved resection margin and extracapsular extension (38, 39) . The most commonly used concurrent chemotherapy regimens in HK are 3-weekly cisplatin 100 mg/m 2 and weekly cisplatin 40 mg/m 2 . However, cisplatin-based CRT substantially increases acute toxicities, necessitating treatment delay in a significant proportion of the patients. It is also associated with increase in severe late toxicities, such as long-term feeding tube dependency, pharyngeal and laryngeal dysfunction, etc. (40) CRT is, therefore, not suitable for all patients, particularly those with suboptimal performance status, advanced age or impaired organ function (41) .
The landmark Bonner study established cetuximab as an alternative agent to concur with RT (42) . Retrospective review demonstrated that cetuximab can improve clinical outcomes regardless of p16 or HPV status (43) . Our local retrospective studies have reported outcome of patients treated with cetuximab-RT. Cheng et al. retrospectively reviewed outcome of a cohort of 31 patients, in which 65% had comorbidities and 35% had a Karnofsky performance status score of 70 or less. Favorable tumor response with complete remission rate of 64% was achieved, with median overall survival (OS) of 25 months (44). Law et al. retrospectively compared 42 patients treated with RT concomitant with either weekly cetuximab or weekly cisplatin (45) . Performance status in the cetuximab arm was poorer than in the cisplatin arm. This study showed a trend of better local control and OS for cisplatin, which echoed the findings of other retrospective single-institution studies conducted in western countries (46) . A meta-analysis that included three prospective and 12 retrospective trials tried to compare efficacy of CRT vs. cetuximab-RT. It concluded that CRT achieved better OS and progression-free survival (PFS) when compared with cetuximab-RT (47). However, retrospective trials are prone to selection bias; therefore, no definite conclusion should be drawn. Panitumumab was not approved for treatment of HNSCC in combination with RT (48) . Addition of targeted therapy, such as cetuximab (49), erlotinib (50) and panitumumab (51), on top of platinum-based CRT failed to show additional benefit compared with CRT alone.
HPVOC is characterized by excellent prognosis and treatment outcome. It was shown to be associated with a 58% reduction in risk of death compared with tobacco-related SCC of oropharynx (52) . Treatment deintensification in HPVOC is currently under extensive research, aiming to reduce treatment toxicities without compromising treatment outcome. Clinical trials are evaluating possibilities of reduction of RT dose, omitting concurrent chemotherapy, reducing chemotherapy dose, replacing chemotherapy with biologicals and using neoadjuvant chemotherapy for patient selection (53) . Results are, so far, very encouraging. However, this is not currently practiced in HK as these results are mainly confined to Phase II data. Careful investigations should be carried out before we can apply these strategies in management on HPVOC locally.
Despite extensive research in the past few decades, neoadjuvant chemotherapy remained to be a controversial issue in management of HNSCC. Early studies, predominantly using cisplatin/fluorouracil (PF), failed to demonstrate OS benefit. A better induction regimen with Docetaxel/cisplatin/fluorouracil (TPF) renewed our interest in neoadjuvant chemotherapy (54) . However, there is limited data to support superiority of induction TPF vs. definitive CRT alone. Most of the trials testing addition of induction TPF to CRT yielded negative results (55) . However, for pragmatic reason, induction TPF is not uncommonly used in HK, especially in T4 or N3 disease. Induction chemotherapy is commonly employed as a bridging therapy while waiting for diagnostic scans, RT planning process, dental, dietetics and speech therapist assessment or surgical intervention. It is also useful in down-staging tumor that is too extensive to be treated upfront or when it is in proximity with critical OAR, causing significant under-dose of planned target volume.
Cisplatin/carboplatin in combination with 5FU is the most commonly used first-line palliative chemotherapy in recurrent or metastatic HNSCC. Although addition of cetuximab is associated with significantly improved OS and response rate (56), it is not currently funded by the government. For the second line setting, methotrexate and paclitaxel are the most commonly used agents. However, they are generally associated with disappointing outcome. A Phase II study demonstrated that a novel pan-PI3K inhibitor, buparlisib, when added to paclitaxel in second line setting, yielded a longer PFS than paclitaxel alone (57) . Afatinib also provides a modest improvement in PFS when compared to methotrexate (2.6 vs. 1.7 months, HR 0.80, P = 0.03) (58) . More recently, immuno-oncology has evolved and become a novel strategy for HNSCC. Immunecheckpoint inhibitors such as pembrolizumab and nivolumab were proven to be efficacious in recurrent HNSCC (59, 60) . Both afatinib and immune-checkpoint inhibitor are currently under active investigations in Asian population including HK.
NPC
Following the pivotal landmark Intergroup 0099 study (61) , multiple studies conducted in endemic areas have confirmed the benefits of addition of chemotherapy to RT (62) (63) (64) . CRT with or without adjuvant chemotherapy has become the mainstay of treatment for locally advanced NPC in HK since late 1990s. Meta-analysis confirmed a small but significant OS benefit by adding chemotherapy, with 6% absolute gain for OS at 5 years (65). While preliminary randomized study reported no significant difference between CRT alone vs. CRT with adjuvant chemotherapy (66) , an individual patient-data network meta-analysis by the MAC-NPC Collaborative Group, with direct and indirect comparison to estimate the relative efficacy between treatment modalities, confirmed that timing of chemotherapy is indeed important (65) . In comparison to RT alone, the HR for OS was 0.65 (95% CI 0.56-0.75) by concurrentadjuvant CRT, 0.77 (95% CI 0.64-0.92) by concurrent-alone CRT and 0.81 (95% CI 0.63-1.04) by induction-concurrent CRT. The hazard ratio for OS showed a trend in favor of concurrent-adjuvant chemotherapy over concurrent-alone chemotherapy (HR 0.85, 95% CI 0.68-1.05) (67) . Other exploratory studies have suggested that 200 mg/m 2 of concurrent cisplatin may be adequate for locoregional control, and it was the adjuvant chemotherapy component, particularly the dose of fluorouracil, that contributed to better distant control (64) . However, compliance with adjuvant chemotherapy is always a major concern and a more personalized approach has been suggested (68) . Induction chemotherapy is gaining popularity in treatment of locoregionally advanced NPC. HKNPCSG NPC-0501 study compared induction-concurrent chemotherapy to concurrent-adjuvant chemotherapy (28) . A total of 803 patients were accrued in this 6-arm trial to explore the therapeutic benefit by changing chemotherapy sequence, fractionation of RT (5 vs. 6 fractions/week) and substitution of 5-FU (PF) with capecitabine (PX) plus cisplatin as induction regimen. Preliminary results revealed that induction PX produced slightly better PFS compared to adjuvant PF (81% vs. 75% at 3 years; P = 0.045). Besides, induction PX brought fewer incidences of neutropenia and electrolyte disturbance than induction PF. More recently, TPF was shown to be superior to PF as induction regimen, with better failure-free survival and OS benefit at 3 years (69) . However this should be interpreted with caution as the dose of PF in control arm of this study was lower than usual, which may exaggerate the survival difference. Long-term efficacy of induction chemotherapy warrants further validation. Traditionally PF has been the first-line regimen of choice for recurrent/metastatic NPC. For patients with previous exposure to cisplatin during radical treatment, consensus is to retry cisplatin if there is a platinum-free period of at least 6 months. In patients with severe ototoxicity or renal impairment, cisplatin may be replaced by carboplatin. Other agents including paclitaxel, capecitabine, gemcitabine and pemetrexed in combination with platinum were extensively evaluated in HK, showing promising results (70) (71) (72) (73) . Recently, a phase III randomized study in mainland China demonstrated PFS (7.0 vs. 5.6 months; P < 0.0001) and OS benefit (29.1 vs. 20.9 months; P = 0.0025) of gemcitabine with cisplatin (GP) over PF as first treatment (74) . Single agent without platinum, e.g. gemcitabine, capecitabine and metronomic cyclophosphamide, is an also acceptable option for heavily pretreated patients. 
Abbreviations: CF, conventional fractionation; AF, accelerated fractionation; RT, radiotherapy; CCRT, concurrent chemo-irradiation; AC, adjuvant chemotherapy; IC, induction chemotherapy; NR, not reported; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival. (62, 85) To compared the results achieved by concurrent chemoradiotherapy vs. radiotherapy alone for nasopharyngeal carcinoma with advanced nodal disease 9902 (63, 64) To compare the benefit achieved by concurrent chemoradiotherapy and/or accelerated fractionation vs. radiotherapy alone with conventional fractionation for patients with T3-4N0-1M0 nasopharyngeal carcinoma 0501 (28) To study the potential therapeutic benefit from changing to an induction-concurrent chemotherapy sequence, replacing fluorouracil with oral capecitabine, and/or using accelerated rather than conventional radiotherapy fractionation 0502 (86, 95) To evaluate the effect of adjuvant chemotherapy in nasopharyngeal carcinoma patients with residual Epstein-Barr Virus DNA following radiotherapy 1001 (87) To evaluate the role of induction chemotherapy using docetaxel, cisplatin and fluorouracil in concurrence with intensity-modulated radiotherapy for local recurrent nasopharyngeal carcinoma Ongoing studies 1002
To study the role of stereotactic radiotherapy in nasopharyngeal carcinoma patients with oligometastasis 1301
To study the long-term efficacy and safety of IMRT treated in all public oncology centers for non-metastatic NPC Planned studies Nivolumab as treatment for recurrent/metastatic nasopharyngeal carcinoma after failing two lines or more previous chemotherapy To evaluate the role of immune-checkpoint inhibitor in concurrence with intensity-modulated radiotherapy for local recurrent nasopharyngeal carcinoma Retrospective studies Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level (88) Survival outcome of patients with nasopharyngeal carcinoma with first local failure (89) Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group (90) Consensus guideline Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines (91) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines (92) Planned consensus guideline Clinical target volume delineation for primary head and neck tumors Targeted therapy including anti-EGFR (gefitinib and cetuxiumab), anti-VEGF/VEGFR (axitinib), multi-kinase tyrosine kinase inhibitor (sunitinib) and Akt inhibitor were also tested in recurrent/ metastatic NPC (75) (76) (77) (78) . Unfortunately, none of them produced promising results. Significant toxicity leading to fatal hemorrhagic events is observed with use of anti-VEGF/VEGFR agent.
Immuno-oncology has become a novel exploratory strategy for NPC. The immunological approach encompasses various strategies namely Epstein-Barr virus (EBV)-directed adoptive and active immunotherapy, administration of antibodies, induction of EBV lytic cycle as well the recent exploration with immune-checkpoint inhibitors. Clinical trials examined the use of CD8 + CTLs through autologous transfer or vaccination with dendritic cells or peptides in patients with recurrent/metastatic NPC have been conducted for the past two decades (79) (80) (81) . The results demonstrated favorable LMP-2 specific immune responses and some durable tumor regression in some patients. Other investigations including T-cell therapy with chemotherapy and the use of novel adenovirus vector for more optimal T-cell expansion have also been reported (80, 82) . An updated result of the use of adenovirus vector for T-cell adoptive therapy either pre-emptively in at-risk patients with no or minimal residual disease or therapeutically in patients with active recurrent or metastatic disease showed that the median PFS and OS were 5.5 months and 38.1 months, respectively (83) . In particular, it was further revealed that disease stabilization in patients with active disease was significantly associated with the functional and phenotypic composition of in vitro-expanded T-cell immunotherapy. These included a higher proportion of effector CD8 positive T-cells and increased number of EBV-specific T-cells with broader antigen specificity. Finally, NPC exhibits high expression of PD-1, and expression of PD-1/PD-L1 correlated with poor outcome. A Phase I study tested safety and antitumor activity of pembrolizumab in PD-L1+ advanced NPC. It demonstrated an objective response rate of 22.2% and disease control rate of 77.8% (84) . At least four Phase II trials are ongoing to investigate the safety and efficacy of immune check inhibitors, including nivolumab, pembrolizumab, PDR001 and avelumab in the recurrent/metastatic setting after prior exposure to platinum-based chemotherapy (NCT02339558, NCT02611960 and NCT02605967, NCT02875613).
Last but not least, in view of the very high incidence of NPC in HK, concerted effort is much needed. Hong Kong NPC study group (HKNPCSG) was first established since 1999. This study group is a collaboration of all public and university cancer centers in HK, aiming to establish the standard of care for NPC through well conducted clinical researches. Tables 3 and 4 summarize some of the key studies reported by HKNPCSG.
Conclusion
Treatment for HNC in HK is in line with international standards. In particular, HK has always maintained its leading and pivotal role in the management of NPC. With concerted efforts through the HKNPCSG, it is expected that HK will continue to produce practice-changing evidence-based medicine in this malignancy through ongoing researches and trials.
